Document is current
Any future updates will be listed below
-
Authors
Bady, Pierre
Marosi, Christine
Weller, Michael
Grønberg, Bjørn H.
Schultz, Henrik
Taphoorn, Martin J. B.
Gijtenbeek, Johanna M. M.
van den Bent, Martin J.
von Deimling, Andreas
Stupp, Roger
Malmström, Annika
Hegi, Monika E.
-
Funding
Funding for this research was provided by:
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (SNF-3103-182821, SNF-3103-163297)
Krebsforschung Schweiz (KFS-4461-02-2018)
- License Information
-
More Information
Article History
Received: 1 February 2022
Accepted: 5 March 2022
First Online: 24 March 2022
Declarations
:
: Patients from the clinical trials cohorts, Lausanne Pilot (LN-Pilot) and EORTC 26981/NCIC CE.3 trial (trial registration number NCT00006353) provided written informed consent for translational research in the context of enrollment into the clinical trial and the study was approved by the ethics committees of the participating centers. The Nordic trial (trial registration number ISRCTN81470623) received Ethics approval under the following numbers 99086, M11-06 T40-09 and 2011/32–32, the latter for molecular analysis. This study has been performed under institutional and international guidelines and regulations as previously reported [CitationRef removed, CitationRef removed, CitationRef removed]. The study was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: P.B.: None. C.M.: None. M.W.: reports grants and personal fees from Apogenix, grants and personal fees from Merck (EMD), grants from Quercis, grants and personal fees from Adastra, personal fees from BMS, Medac, Merck Sharp & Dohme, Nerviano, Novartis, Orbus, Philogen, and y-Mabs. B.H.G.: None. H.S.: None. M.J.B.T.: None. J.M.M.G.: None. M.J.vdB.: reports consulting fees from Abbvie, Celgene, Agios, Boehringer Ingelheim, Bayer, Carthera, Genenta, Nerviano, Boston pharmaceuticals and research funding from Abbvie. A.v.D.: reports a pending patent: DNA methylation-based method for classifying tumor species (EP16710700.2). R.S.: reports consulting for CarThera; Celularity; CranioVation/Alpheus; Hemispherian; Insightec; GT Medical Technologies; Northwest Biotherapeutics; TriAct. A.M.: None. M.E.H.: reports consulting fees from Hemispherian; NOXXON.
